In summary, this is the first report describing the use of CRISPR/Cas9 genome editing to completely truncate human BCR-ABL oncoprotein fusion in order to prevent its tumorigenic abilities in an in vitro as well as in an in vivo CML model. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.